Statkraft AS: Release of fourth quarter results 2022 and annual report for 2022
Statkraft discloses fourth quarter results 2022 and the annual report for 2022 on Thursday 2 March 2023 at 08:00 a.m. CET.
Material will be available on Statkraft’s website www.statkraft.com and Oslo Stock Exchange’s news service www.newsweb.no.
09:30 a.m. CET: Statkraft presents the results in a webcast at www.statkraft.com. The presentation will be held in English.
Arild Ratikainen, Investor Contact, tlf.: +47 971 74 132, e-mail: email@example.com
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.6.2023 22:00:00 CEST | Press release
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 36,006 divided into 36,006 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are
NORBIT - Enters into a NOK 80 million agreement for contract manufacturing8.6.2023 21:00:00 CEST | Press release
Trondheim, 8 June 2023: NORBIT is pleased to announce that segment PIR has entered into an agreement with an undisclosed Nordic customer for delivery of tailored electronics for data collection and transmission to the clients’ cloud solution. Deliveries are scheduled over a period of 30 months, and the agreement has an estimated value of approximately NOK 80 million over the said period. “The collaboration with this client started with R&D services and industrialisation. With the client’s success in their core market, we are pleased to see that we can enable their industrial scalability from our Selbu factory”, says Per Jørgen Weisethaunet, CEO of NORBIT. For further queries, please contact: Per Jørgen Weisethaunet, CEO, +47 959 62 915 Per Kristian Reppe, CFO, +47 900 33 203 About NORBIT ASA NORBIT is a global provider of tailored technology to selected applications, solving challenges and promoting sustainability through innovative solutions, in line with its mission to Explore More.
Norsk Hydro: Hydro øker prisen midlertidig i tilbudsprosessen for Alumetal8.6.2023 20:06:52 CEST | Pressemelding
Hydro øker tilbudsprisen midlertidig i den pågående tilbudsprosessen for 100 prosent av aksjene i Alumetal til PLN 82,00 per aksje. Den økte tilbudsprisen vil være gjeldende frem til og med 15. juni i år. Hydro tilbyr PLN 82,00 per aksje i Alumetal til alle aksjonærer som tegner seg for salg av aksjer frem til og med kl. 23:59 den 15. juni 2023, herunder de aksjonærene som har tegnet seg for salg av aksjer før prisøkningen trer i kraft (med unntak for ca 32,7 prosent av aksjene eid av IPO30 UNIPESSOAL LDA som vil erverves av Hydro til PLN 78,69 per aksje). Fra og med 16. juni vil tilbudsprisen igjen bli redusert til den opprinnelige prisen på PLN 78,69 per aksje. Den midlertidige prisøkningen tar sikte på å belønne investorer som responderer tidlig i tilbudsprosessen, for å oppfylle Hydros forbehold om kjøp av minimum 50 prosent av aksjene i Alumetal. Omkring 39 prosent av selskapets aksjer er allerede tegnet i tilbudsprosessen, inkludert aksjene som eies av to av medlemmene i Alumetal